Fundraising FoxIo Therapeutics
Spring, US · Founded 2010 · Texas corporation
Find your way into Io Therapeutics
Sign up to find every way you can get introduced to Io Therapeutics
- Your email: who you already know at Io Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Io Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Io Therapeutics develops small molecule retinoid drugs, including IRX4204 and IRX5183, as potential treatments for oncology, neurologic, autoimmune, and dermatologic conditions such as psoriasis. It is a biopharmaceutical company focused on clinical-stage therapeutic product development.
Founders & leadership
Io Therapeutics was founded in 2010 by Roshantha A. Chandraratna, Rosh Chandraratna, Martin Sanders, M.D., Vidyasagar (Sagar) Vuligonda, Ph.D., and Rosh Chandraratna, Ph.D.
Board
Reported raises · per SEC filings
Form D private placements$4.6M disclosed across 2 rounds · 2013–2023
▶$4.2MraisedAug 2023 · 19 investors · BiotechnologyRule 506(b)
- Sharon LewExecutive Officer
- Sahani ChandraratnaDirector
- Vidyasagar VuligondaExecutive Officer
- Martin SandersExecutive Officer
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- First sale
- Feb 2023
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$443.5KraisedJan 2014 · 4 investors · BiotechnologyRule 506(b)
- Scott ThacherDirector
- Martin E. SandersExecutive Officer, Director
- Roshantha A. ChandraratnaExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $443.5K
- First sale
- Dec 2013
- Incorporated
- Corporation, California, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Companies working in the same space as Io Therapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Io Therapeutics do?
- Io Therapeutics develops small molecule retinoid drugs, including IRX4204 and IRX5183, as potential treatments for oncology, neurologic, autoimmune, and dermatologic conditions such as psoriasis. It is a biopharmaceutical company focused on clinical-stage therapeutic product development.
- Who founded Io Therapeutics?
- Io Therapeutics was founded by Roshantha A. Chandraratna, Rosh Chandraratna, Martin Sanders, M.D., Vidyasagar (Sagar) Vuligonda, Ph.D., Rosh Chandraratna, Ph.D in 2010.
- How much funding has Io Therapeutics raised?
- Io Therapeutics has disclosed $4.6M raised across 2 rounds.
- Where is Io Therapeutics headquartered?
- Io Therapeutics is headquartered in Spring, US.